

Supplementary Table 4. Subgroup analyses of the primary composite outcome and ICU admission with IMV in the hypertensive patients with coronavirus disease 2019

Characteristic	No. (%)		OR (95% CI)	
	Primary outcome (n=144)	ICU admission with IMV (n=17)	Primary outcome	ICU admission with IMV
Age, yr				
<65	33 (4.5)	5 (0.7)	0.65 (0.29–1.48)	0.85 (0.10–7.70)
≥65	111 (17.2)	12 (1.9)	0.96 (0.60–1.51)	1.80 (0.39–8.29)
Sex				
Men	78 (13.7)	9 (1.6)	0.77 (0.43–1.36)	0.84 (0.17–4.08)
Women	66 (8.2)	8 (1.0)	0.68 (0.39–1.18)	2.15 (0.26–17.55)
Diabetes mellitus				
Yes	113 (14.1)	14 (1.8)	0.75 (0.46–1.23)	1.35 (0.30–6.09)
No	31 (5.4)	3 (0.5)	0.48 (0.23–0.99)	0.72 (0.07–7.96)
Hyperlipidemia				
Yes	78 (11.2)	8 (1.1)	0.50 (0.29–0.86)	1.43 (0.17–11.71)
No	66 (9.8)	9 (1.3)	1.05 (0.59–1.88)	1.28 (0.23–6.20)
Cardiovascular disease				
Yes	103 (17.3)	16 (2.7)	0.66 (0.41–1.06)	1.35 (0.38–4.79)
No	41 (5.3)	1 (0.1)	1.25 (0.54–2.87)	NA
Chronic kidney disease				
Yes	17 (30.9)	2 (3.6)	0.49 (0.11–2.13)	NA
No	127 (9.6)	15 (1.1)	0.74 (0.49–1.13)	1.12 (0.32–4.01)
Chronic pulmonary disease				
Yes	42 (15.3)	7 (2.5)	1.66 (0.70–3.93)	NA
No	102 (9.3)	10 (0.9)	0.58 (0.37–0.91)	0.63 (0.16–2.44)
Treatment for diabetes mellitus				
Insulin	8 (30.8)	2 (7.7)	NA	NA
Non-insulin	136 (10.1)	15 (1.1)	0.69 (0.47–1.03)	1.12 (0.32–4.00)
Statin				
Yes	73 (11.2)	8 (1.2)	0.59 (0.33–1.05)	1.45 (0.18–11.92)
No	71 (9.9)	9 (1.3)	0.88 (0.51–1.51)	1.22 (0.25–5.94)
Antithrombotic agents				
Yes	73 (18.8)	10 (2.6)	0.44 (0.25–0.77)	1.10 (0.23–5.30)
No	71 (7.2)	7 (0.7)	1.26 (0.68–2.34)	1.67 (0.20–13.95)
Inhaled corticosteroids				
Yes	23 (22.6)	5 (4.9)	1.72 (0.52–5.64)	NA
No	121 (9.5)	12 (0.9)	0.67 (0.44–1.02)	0.82 (0.22–3.04)

ICU, intensive care unit; IMV, invasive mechanical ventilation; OR, odds ratio; CI, confidence interval; NA, not applicable.